REVISTIM-XX: Effects of tDCS Combined With VR on Anxious Ruminations in Healthy Subjects With a Vulnerability to Rumination

Sponsor
Nantes University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03915041
Collaborator
(none)
20
1
2
15
1.3

Study Details

Study Description

Brief Summary

This study proposes: to evaluate 1) whether the combination of virtual reality (VR) and active tDCS provides better rumination attenuation than the combination of VR and tDCS placebo 2) the acceptability and experiential experience of combining these two well known medical devices.

Condition or Disease Intervention/Treatment Phase
  • Device: VR + active brain stimulation
  • Device: VR +sham brain stimulation
N/A

Detailed Description

Inclusion visit:
  • Confirmation of eligibility criteria

  • Written informed consent

Visit 1 and 2 (or end of study visit) :
Before first ruminations induction :
  • Completion of Brief State Rumination Inventory (BSRI), State-Trait Anxiety (STAI), Inventory, Visual Analogic Scale (VAS), Ruminative Response Scale - Short Form (RRS-SF), Beck depression Inventory (BDI)

  • EEG recording

Then Procedure for inducing ruminations using a pre-recorded voice listened to in an audio headset alternating statements promoting a positive, neutral and negative introspection and self-judgment attitude (the latter are heard at the end to initiate the rumination process) over 8 minutes

Then

  • Completion of Brief State Rumination Inventory (BSRI), Inventory, Visual Analogic Scale (VAS), Beck depression Inventory (BDI),

  • EEG recording

  • Pulse and blood pressure measurements

Then immersion in a relaxing virtual environment for 20 minutes with active or sham placebo.

• Cutaneous conductance measurement and eye-tracking during immersion

At the end of immersion :
  • Completion of Brief State Rumination Inventory (BSRI), Inventory, Visual Analogic Scale (VAS), Beck depression Inventory (BDI), IGroup presence questionnaire (IPQ)

  • Pulse and blood pressure measurements

Then again procedure for inducing ruminations .

At the end of ruminations induction :
  • Completion of Brief State Rumination Inventory (BSRI), State-Trait Anxiety (STAI), Inventory, Visual Analogic Scale (VAS), Beck depression Inventory (BDI), tolerance questionnaires

  • Debriefing

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Other
Official Title:
Effects of tDCS Combined With Virtual Reality on Anxious Ruminations in Healthy Subjects With a Vulnerability to Rumination
Actual Study Start Date :
May 15, 2019
Actual Primary Completion Date :
Aug 14, 2020
Actual Study Completion Date :
Aug 14, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: VR + active brain stimulation

Exposure to a virtual reality world with active transcranial electric stimulation

Device: VR + active brain stimulation
Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)

Sham Comparator: VR + sham brain stimulation

Exposure to a virtual reality world with sham transcranial electric stimulation

Device: VR +sham brain stimulation
Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)

Outcome Measures

Primary Outcome Measures

  1. Change in anxious ruminations after anodal tDCS and virtual reality [within 1 week]

    Change in anxious ruminations after anodal tDCS and virtual reality will be evaluated to compare the effects of tDCS associated with virtual reality versus virtual reality alone (+ tDCS placebo) to reduce ruminations. Evaluate with Brief State Ruminative Inventory (BSRI). It is a scale with 8 items. Each item is VAS with a score ranging between 0 and 100. The total score is sum of each item score (Total /800)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Without any particular ethnic and psychosocial criteria

  • Subject to ruminations (personality trait) documented by a RRS-SF score >30

  • Subjects with score to BDI scal <14 assessed during first visit

  • Subjects without psychiatric or addictive disorders.

  • Subjects who do not meet all the diagnostic criteria for an anxiety disorder or characterized depressive episode.

Exclusion Criteria:
  • contraindication to tDCS (neurosurgical history, intracranial device, skin problems)

  • current virtual reality intolerance

  • history of psychiatric or addictive disorders

  • Use of psychotropic drugs

  • Use of non psychotropic treatments significantly influencing mood or level of anxiety

  • pregnant or breast-feeding women

  • Neurological pathology, locomotor disability, or sensory (vestibular, visual, auditory ...)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Nantes France

Sponsors and Collaborators

  • Nantes University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT03915041
Other Study ID Numbers:
  • RC17_0390
First Posted:
Apr 16, 2019
Last Update Posted:
Aug 27, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Nantes University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 27, 2020